Angiotensin-converting enzyme inhibitors (ACEI) can reduce excessive inflammation and increase intracellular antiviral responses, while in patients with COVID-19, hypertension inhibits viral clearance and worsens excessive airway inflammation (66). This evidence concerns the gene ACE and COVID-19.